HomeHealthMedicineFerring Pharmaceuticals to Present New Data Highlighting Future Assisted Reproductive Technology Market...

Ferring Pharmaceuticals to Present New Data Highlighting Future Assisted Reproductive Technology Market Trends at ASRM 2022 Scientific Congress & Expo

PARSIPPANY, NJ, October 19, 2022 /PRNewswire/ — Ferring Pharmaceuticals announced today that it will present a company-sponsored executive summary highlighting an in-depth analysis of future trends in the assisted reproductive technology (ART) market and will also host a product theater at the American Society for Reproductive Medicine (ASRM) 2022 Scientific Congress & Expo takes place October 22-26 in Anaheim, California.

(PRNews photo/Ferring Pharmaceuticals)

We are excited to share new data and perspectives at ASRM to contribute to the robust congressional program that will continue to advance the field of reproductive medicine,” said Elizabeth GarnerMD, MPH, Chief Scientific Officer, Ferring Pharmaceuticals USA”Ferring’s continued commitment to science sharing and supporting new standards of care for aspiring parents is a top priority for the company.”

Ferring’s data presentation used national summaries of gonadotropin use in the US compared to data provided by the Disease Control Centers (CDC), to provide a forecast of future trends in the ART market. This research provides interesting insights into the expected future demand for treatments and helps ensure resources are available for people building their families.

“Following the immediate impact of the global COVID-19 pandemic, with nearly 90% of clinics closed and patients reluctant to seek care, we have seen a significant increase and pent-up demand for fertility treatments, and it is of critical that we better understand the potential market dynamics so that we can be prepared to support aspiring parents looking to build their families,” said Fady Sharara, MD, FACOG, Virginia Center for Reproductive Medicine, and lead author of the abstract. “I have personally seen the growth in the use of gonadotropin within my own practice, and it is important data like we present at ASRM that will provide the potential market trends that healthcare providers and staff need to prepare in their own clinics.”

Must Read
Samulski Receives Inaugural Award for Pioneering Gene Therapy

In addition to the data presentation, Ferring will host a product theater session titled: “Natural Cycle Frozen Embryo Transfer (FET) – is that the new program?” led by Dr. Valerie Baker, Johns Hopkins University School of Medicine and dr. Denis Vaughan, Boston IVF. There is an increasing trend toward the performance of natural cycle FETs over the current standard of programmed FETs due to the potential obstetric and clinical benefits associated with natural cycle FETs. The product theater includes a review of the literature comparing natural cycle and programmed FETs, and a presentation detailing the results of Boston IVF’s natural cycle FET data and their experience incorporating natural cycle FETs into their laboratory and clinical workflow are assessed.

The details of Ferring’s product theater session and abstract presentation are as follows:

Ferring Product Theater Session
Title: Natural Cycle FET – is that the new program?
Date and time: Monday, October 24, 2022; 10:05 am10:45 a.m. PDT

(PSW-08) E-Poster Abstract Station: W8
Title: Gonadotropin usage data can be used as an indicator of US Assisted Reproductive Technology (ART) market dynamics
Date and time: Wednesday, October 26, 2022; 6:45 am7:45 a.m. PDT

For more information on Ferring’s abstract presentation, visit asrmcongress.org/

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. In the United StatesFerring is a leader in reproductive medicine and maternal health, and in specialties within gastroenterology and orthopedics. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio of treatments from conception to birth. Founded in 1950, Ferring now employs approximately 6,000 people worldwide, has its own subsidiaries in nearly 60 countries and sells its products in 110 countries.

Must Read
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

More information on www.ferring.comor contact us at Twitter, facebook, Instagram, LinkedIn and YouTube.

For more information, please contact

Lisa Perdomo
Director, Brand communication
Ferring Medicines



View original content to download multimedia:https://www.prnewswire.com/news-releases/ferring-pharmaceuticals-to-present-new-data-highlighting-future-assisted-reproductive-technology-market-trends-at-asrm-2022-scientific-congress- -expo-301652659.html

SOURCE Ferring Pharmaceuticals



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments